Allisartan - Allist Pharmaceuticals/Shenzhen Salubris Pharmaceuticals
Alternative Names: Allisartan isoproxil - Allist Pharmaceuticals/Shenzhen Salubris Pharmaceuticals; Shun Li Tan®; XinlitanLatest Information Update: 02 Oct 2021
At a glance
- Originator Allist Pharmaceuticals
- Developer Allist Pharmaceuticals; Shenzhen Salubris Pharmaceuticals
- Class Antihypertensives; Small molecules
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 13 Feb 2019 Chemical structure information added
- 31 Mar 2010 Allist Pharmaceuticals completes a phase III trial in Hypertension in China (ChiCTR-TRC10000885)
- 31 Jan 2010 Allist Pharmaceuticals completes a phase II trial in Hypertension in China (ChiCTR-TRC10000886)